Clinical Trial: Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients.

U.S., March 13 -- ClinicalTrials.gov registry received information related to the study (NCT07465718) titled 'Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients.' on March 06.

Brief Summary: The goal of this clinical trial is to learn if a new trientine tetrahydrochloride (TETA 4HCl) formulation administered once a day compared to d-Penicillamine (DPA) as a first line treatment for people living with Wilson's disease (WD) is effective and safe. The study is enrolling children aged 8 years and older weighing at least 55 lb (25 kg) and adults with a recent diagnosis of WD. People recently diagnosed with WD, may be eligible for the study if they have either not started copper chelati...